Basque health research institute specializing in cancer biomarkers, congenital anomaly surveillance, regenerative bone medicine, and molecular diagnostics.
Biogipuzkoa is a health research institute based in Donostia-San Sebastián (Basque Country, Spain) that conducts translational biomedical research spanning epidemiology, cancer diagnostics, regenerative medicine, and antimicrobial technologies. Their work bridges clinical research with applied medical technology — from tracking birth defects across European cohorts to developing bone repair strategies and circular DNA-based diagnostic tools. They also contribute to medical device development and testing, and participate in European efforts to communicate gene and cell therapy advances to the public.
ESCALON (hepatobiliary cancer biomarkers), CIRCULAR VISION (circular DNA diagnostics for lung cancer and IBD), and EuroGCT (cell/gene therapy communication) all center on oncology and advanced diagnostics.
EUROlinkCAT established linked cohorts tracking children with congenital anomalies across Europe, and I-MOVE-plus monitored vaccine effectiveness at population scale.
HEALIKICK develops modular bone fracture repair using growth factors and implant coatings, while TBMED provides a testing bed for high-risk medical device development.
FLEXPOL developed antimicrobial flexible polymers using nanoimprinting for hospital environments, showing materials science capability.
CIRCULAR VISION employs microfluidics and lab-on-a-chip approaches for DNA-based disease diagnostics, signaling a move toward precision diagnostic platforms.
In their early H2020 period (2015–2019), Biogipuzkoa focused on population-level health surveillance — tracking congenital anomalies, vaccine effectiveness, and antimicrobial solutions for hospitals. From 2019 onward, their work shifted decisively toward molecular-level precision medicine: cancer biomarkers, circular DNA diagnostics, CRISPR-based tools, bone tissue engineering, and medical device innovation. This evolution reflects a clear move from epidemiological observation to interventional biomedical technologies.
Biogipuzkoa is building toward molecular diagnostics and advanced therapies, making them an increasingly relevant partner for projects involving liquid biopsy, gene editing, or personalized medicine.
Biogipuzkoa consistently participates as a partner or third party — they have never coordinated an H2020 project, which suggests they contribute specialized research capacity rather than leading large-scale project management. With 142 unique partners across 30 countries, they are well-networked and comfortable in large international consortia. Their two third-party roles (I-MOVE-plus, TBMED) indicate they are also called upon as domain experts by other institutions who value their clinical or technical input.
Extensive European network of 142 unique consortium partners spanning 30 countries, reflecting broad reach across the continent. Their participation in projects like ESCALON (European-Latin American network) also gives them connections beyond Europe.
Biogipuzkoa sits at a distinctive intersection of epidemiological surveillance and molecular precision medicine — few health research institutes bridge population health data (birth defect registries, vaccine monitoring) with bench-level tools like CRISPR-Cas and microfluidic diagnostics. Based in the Basque Country with strong hospital links, they offer a clinical research environment where new diagnostic and therapeutic approaches can be developed close to patient populations. Their willingness to serve as third-party experts also makes them an accessible, low-barrier collaboration partner for consortia that need specific biomedical expertise without complex partnership overhead.
